Skip to main content

Table 2 Response to treatment during entecavir therapy (n = 55) *

From: Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients

  Response to treatment over time (weeks)
  pre (baseline) 2nd 4th 12th 16th 24th 48th
HBVDNA-negation 0 8 (14.5) 13 (23.6) 17 (30.9) 21 (38.2) 28 (50.9) 43 (78.2)g
HBeAg-negation 0 0 0 3 (5.5) 3 (5.5) 6 (10.9) 9 (16.4)h
HBeAg/HBeAb seroconversion 0 0 0 1 (1.8) 2 (3.6) 4 (7.3) 8 (14.5)
ALT normalization 0 0 7 (12.7) 31 (56.4) 39(70.9) 47 (85.5) 46 (83.6)
ALT normal/HBeAg & HBVDNA-negation 0 0 0 3 (5.5) 3 (5.5) 6 (10.9) 8 (14.5)
HBV DNA (Log, copies/mL) 7.9 ± 1.1 5.1 ± 1.21d 4.6 ± 1.3d 3.8 ± 0.9d 3.6 ± 0.8d 3.3 ± 0.7d 2.9 ± 0.5df
T-lymphocyte subpopulations (percentage)        
   CD3+T-lymphocyte 45.1 ± 9.0 45.3 ± 8.9 45.4 ± 8.9 47.4 ± 8.6 48.2 ± 8.7a 50.6 ± 8.4c 54.9 ± 7.9df
   CD4+T-lymphocyte 28.1 ± 5.7 28.2 ± 5.5 28.4 ± 5.6 30.6 ± 5.1b 31.7 ± 5.4c 33.6 ± 4.6d 36.5 ± 3.7dg
   CD8+T-lymphocyte 40.0 ± 6.7 39.9 ± 7.1 39.8 ± 7.0 36.7 ± 6.6b 35.4 ± 6.2c 32.8 ± 6.2d 28.9 ± 28.9dg
   CD4+/CD8+T-lymphocyte ratio 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.2 0.9 ± 0.3b 0.9 ± 0.3d 1.1 ± 0.3d 1.3 ± 0.3dh
Biochemichal measurements        
   Serum ALT level (IU/L) 251.4 ± 66.1 101.6 ± 43.4d 75.7 ± 23.4d 42.6 ± 15.8d 40.5 ± 15.0d 37.0 ± 13.32d 32.9 ± 6.5df
   Serum AST level (IU/L) 195.7 ± 81.6 73.9 ± 62.3d 57.6 ± 18.9d 39.5 ± 14.0d 38.2 ± 14.5d 35.7 ± 8.1d 29.9 ± 4.7dh
   Serum total bilirubin level (μmol/mL) 26.7 ± 18.1 11.0 ± 4.9d 10.9 ± 4.1d 10.7 ± 3.9d 10.9 ± 4.1d 10.3 ± 3.4d 9.6 ± 3.1d
  1. *ALT, alanine aminotransferase; AST, aspartate aminotransferase; Normal values: ALT, ≤40 IU/L; AST, ≤40 IU/L; total bilirubin ≤17.1 μmol/mL; CD3+T, 61.1~77.0; CD4+T, 25.8~41.6; CD8+T, 18.1~29.6; CD4+/CD8+T ratio, 1.57~2.93.
  2. † Date are expressed as no. (%);
  3. ‡ Data are expressed as mean ± SD.
  4. ap < 0.05, bp < 0.01, cp < 0.001, dp < 0.0001 vs pre;
  5. fp < 0.01, gp < 0.001, hp < 0.0001 vs 24th.